Order results by:
| Issue | Title | |
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... . Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... расходы бюджета здравоохранения и социального обеспечения субъектов Российской Федерации; 2) оценить ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... prices. The budget impact analysis of the influence of netakimab inclusion in the therapy for patients ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... to perform the cost-effectiveness analysis, incremental analysis, and «budget impact» analysis. Results ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... ’ medical records. The cost-effectiveness analysis, incremental analysis, and «budget impact» analysis were ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... . The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... (ведолизумаба и различных ингибиторов ФНО-α) у взрослых пациентов со среднетяжелым или тяжелым активным язвенным ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... -effectiveness ratio (CER) and budget impact analysis (BIA) were performed. All calculations were made in the MS ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... , sorafenib 651 mg/day (after dose reduction), and chemotherapeutic agents. As part of the budget impact ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... consisted of two parts: clinical and economic study and budget impact analysis. We used cost minimization ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... взрослым больным СД2, а также данных о фактических государственных закупках препаратов классов иНГЛТ-2 и ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... technology medical care list part 1 (HТMC 1). Budget impact analysis compared the costs of using ICD within ..." | ||
| Vol 10, No 1 (2017) | PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS | Abstract similar documents |
| A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina | ||
| "... . Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used. Results ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... ,165.00 rubles (–0.4%). The budget impact analysis showed that an increase in the proportion of patients ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... parameters, budget impact analysis were carried out. Results. The total medical costs for CP/EP + ATZ course ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... of one patient annual therapy by 2.68 mln. rubles. Budget impact analysis evidences that Eltrombopag ..." | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... перечень жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП). Материалы и методы ..." | ||
| Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
| E. V. Biryukova, V. I. Ignat’eva | ||
| "... На настоящий момент предложено несколько вариантов старта и интенсификации инсулинотерапии у ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... (treated separately), ART program cycle, relief of complications. As part of the budget impact analysis ..." | ||
| Vol 16, No 1 (2023) | Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 | Abstract similar documents |
| D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin | ||
| "... follitropin alfa, there was a 103% increase in savings. Budget impact analysis determined that switching 25 ..." | ||
| Vol 10, No 2 (2017) | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA | Abstract similar documents |
| N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov | ||
| "... . Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies | Abstract similar documents |
| K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina | ||
| "... of the budget impact analysis included the costs required for the ovarian stimulation of patients distributed ..." | ||
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... and third lines of NSCLC therapy. The budget impact analysis demonstrated that if all patients in the target ..." | ||
| Vol 10, No 2 (2017) | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov | ||
| "... бромид, а также направления и ожидаемые объемы минимизации затрат бюджета здравоохранения. Материалы и ..." | ||
| 1 - 24 of 24 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
